In the treatment of diabetes, the positive correlation between weight gain and glycaemic control is well known. Inappropriate weight gain has been demonstrated in landmark diabetes studies, with insulin or oral antidiabetic drugs. Weight increase is associated with accelerated deterioration in beta-cell function in type II diabetes, and increases in hypertension and lipid levels in both type I and type II diabetes. Concerns about increasing weight may be a barrier to initiation or to intensification of insulin therapy. Insulin introduction may be delayed in type II diabetes, and patients may under-dose their insulin to avoid gaining weight. Insulin detemir is a new long-acting soluble insulin analogue where protraction is achieved by reversible binding to albumin. As a result, it has consistent absorption and low variability from injection to injection. Studies of insulin detemir in basal-bolus regimens in type I and type II diabetes have shown significantly less weight gain compared with NPH. There is speculation about potential mechanisms for these outcomes and results from ongoing investigations are awaited. The insulin detemir data suggest that weight gain with insulin therapy is not inevitable. The potential therefore exists for improving glycaemic control while maintaining weight stability, resulting in immediate and long-term benefits for patients.
Introduction
As the importance of achieving HbA 1c targets is increasingly emphasised, more people with type I diabetes are adopting intensified insulin regimens, and people with type II diabetes are adding insulin to their oral antidiabetic drug (OAD) regimens or relying entirely on insulin. Current ADA guidelines recommend an HbA 1c of o7%, with a need to review and change the treatment regimen if values are consistently 48%.
1 However, treatment with insulin is not problem-free.
The risk of severe hypoglycaemia increases when normoglycaemia is the goal. 2 In both type I and type II diabetes, inappropriate weight gain associated with insulin may also occur. In many studies where weight gain was associated with insulin or insulin plus OAD therapy, there was a positive correlation between weight gain and glycaemic control. Weight gain often increased as glycaemic control improved, demonstrated by decreases in HbA 1c values. 3, 4 For diabetes patients, gaining weight can be especially undesirable as it is associated with poor cardiovascular outcomes 5 and other morbidity, and leads to increasing insulin resistance. 6, 7 This weight gain may also act as a psychological barrier to the effective initiation or intensification of insulin therapy for people who would benefit from it. Insulin detemir (Novo Nordisk A/S, Denmark) is a new basal analogue insulin. In large studies of basal-bolus therapy with human insulin or the rapid-acting analogue, insulin aspart, in type I and type II diabetes, insulin detemir has been shown to be consistently associated with weight stability compared with NPH insulin. This paper discusses the importance of effective weight management for people with diabetes, and illustrates the relative lack of weight gain in studies with insulin detemir.
Weight gain: a barrier to insulin therapy
Extent of weight gain in type II diabetes Treatment-associated weight gain occurs to the greatest extent in type II diabetes, but may also be of clinical concern in type I diabetes. Patients with type II diabetes are often overweight at diagnosis, 8 and further weight gain is undesirable. In the UK Prospective Diabetes Study (UKPDS) of type II diabetes, all therapies (diet, OADs or insulin) were associated with weight gain over the study period of 15 y. 9 Weight increased for conventional and intensive therapy groups (conventional therapy target F fasting plasma glucose (FPG) o15 mmol/l; intensive therapy targets F FPG o6 mmol/l and preprandial glucose of 4-7 mmol/l). The most weight gain occurred in the group treated with insulin for optimal glycaemic control ( Figure 1 ). In the cohorts followed for 10 y, mean weight increases were 3.1 kg greater in the intensive treatment group compared with the conventional group (99% CI,À0.9 to 7.0, Po0.0001). 4 In the intensive group, weight increases were 1.7 kg greater in those taking glibenclamide (Po0.001), 2.6 kg greater in those taking chlorpropamide (Po0.001), and 4.0 kg greater in patients receiving insulin (Po0.0001), compared with the conventional group. In all patients receiving intensive treatment (with OADs and/or insulin), most weight gain occurred during the first year. Indeed, all OADs may be associated with weight gain, although metformin is sometimes helpful in limiting the weight gained with insulin therapy.
Prognosis in type II diabetes
In some patients with type II diabetes, diabetes may be controlled with effective weight reduction, or the doses of antidiabetic drugs (including insulin) may be decreased as weight loss occurs. 10 Recommendations to optimise therapy in type II diabetes now encourage the use of multiple OADs plus the addition of insulin, or transfer to an insulin-only regimen. The UKPDS demonstrated a progressive deterioration in beta-cell function over a 6-y period in type II diabetes in patients on diet or OAD therapy, regardless of the antidiabetic therapy employed. 11 Using homeostasis model assessment (HOMA), beta-cell function decline was confirmed. This included treatment with sulphonylureas, where beta-cell function improved in the first year then progressively declined (from 46% at baseline, to 78% at 1 y, to 52% at 6 y). Thus, in many patients with type II diabetes, insulin becomes a physiological necessity as the disease progresses. When insulin resistance predominates, patients are likely to require very large doses of insulin. Jacobs et al 12 demonstrated an association between insulin dose and obesity risk, and patients may be caught in a vicious circle of obesity leading to increased insulin resistance, requiring higher doses of insulin.
Consequences of weight gain in type II diabetes
In patients with type II diabetes, weight gain is important for two main reasons. The desire to avoid obesity or increasing obesity may act as a psychological barrier to the timely introduction of insulin in type II diabetes. 13 This is an important factor which may delay the introduction of insulin when maximal doses of OADs are not controlling glycaemia.
In developed countries, the prevalence of obesity continues to increase in the whole population.
14 With increasing obesity, the risk of serious diseases (including cardiovascular disease, hypertension, some cancers and type II diabetes) also increases. 15 Additionally, there are important psychological consequences of obesity such as poor selfesteem and increased incidence of depression; 16 depression is also prevalent in people with type I or type II diabetes. 17 However, even in populations without diabetes, weight loss and long-term weight control are extremely difficult for many people. 18 A strong desire to avoid weight gain may therefore have negative consequences for long-term therapies that are associated with increasing weight. Due to its negative effects on well-being, weight gain may also contribute to the occurrence of emotional burnout associated with the demands of diabetes, leading to avoidance or neglect of diabetes treatment.
19
Weight gain also adversely affects the prognosis of people with type II diabetes. In the metabolic syndrome (syndrome X), obesity and type II diabetes are clearly associated. The risk factors of central obesity, insulin resistance and hyperglycaemia, dyslipidaemia with high triglycerides and low HDL cholesterol, and hypertension are associated with increased risks of cardiovascular disease and diabetes. 20, 21 Increasing insulin resistance with increasing obesity and with central obesity demonstrated by waist-to-hip ratio (WHR) have been shown in studies of patients with type II diabetes. 7, 22 Inappropriate weight gain also occurs with type I diabetes For patients with newly diagnosed type I diabetes, weight gain may be desirable when a preceding period of glycosuria and weight loss has often occurred. However, these patients may subsequently gain weight beyond the ideal. The Diabetes Control and Complications Trial (DCCT) compared intensive insulin therapy (IIT) with conventional insulin therapy (consisting of one or two insulin injections) in type I diabetes. Patients on IIT gained significantly more weight in the first year than those on conventional therapy (5.174.6 vs 2.473.7 kg, respectively, Po0.0001).
3 Weight change was also investigated in the Wisconsin Epidemiologic Study of Diabetic Retinopathy in type I diabetes. 23 Patients (n ¼ 405)
were followed for 4 y. Mean body weight increased significantly over this time and weight gain was associated with an increased number of insulin injections and the adoption of a basal/bolus regimen. Weight gain may also be a barrier to insulin therapy and IIT in type I diabetes Burnout is popularly perceived as a particular problem in young adults with type I diabetes, and for this population weight gain is often not recognised as a major concern. In fact, both of these views are misconceptions. Burnout may affect people with type I or type II diabetes, 19 while it is not unusual to find insulin doses being omitted or reduced by many patient populations in order to directly control weight. Bryden et al 24 assessed
eating habits in adolescents with type I diabetes (age 11-18 y) and the same population 10 y later (n ¼ 65). During adolescence, 30% of women identified that they had been under-using insulin for reasons of weight control. For men and women, assessments of shape concern and weight concern significantly increased between baseline and follow-up.
Patients may also resist recommendations to intensify their insulin therapy due to a desire to avoid weight gain resulting in sustained suboptimal glycaemia.
Consequences of weight increase in type I diabetes
In type I diabetes, weight gain has been associated with hypertension and increased lipid levels. Weight gain may also be associated with increasing insulin resistance in this group of patients. Williams et al 6 investigated 24 patients with type I diabetes in a euglycaemic-hyperinsulinaemic clamp study. In this group, WHR was found to be a predictor of the presence of insulin resistance. Other key clinical predictors of insulin resistance in this study were hypertension and increased HbA 1c . In the DCCT, after a mean followup of 6.1 y, the intensively treated patients who gained the most weight had the largest increases in blood pressure, total cholesterol, and LDL cholesterol. 5 Patients on intensive therapy were stratified into quartiles of weight gain ( Figure 2 ). For all quartiles, intensive therapy resulted in similar improvements in HbA 1c values. In the first quartile of weight gain, there was no significant weight change as compared with baseline, and improvements in mean cholesterol and triglyceride levels were experienced. In the fourth quartile, total cholesterol, LDL and blood pressure increased compared with baseline, and total cholesterol, LDL and blood pressure all increased compared with the first quartile at follow-up (Figure 3) .
The increases in cholesterol and blood pressure seen in this study in the group that gained the most weight could possibly be associated with an increase in risk of cardiovascular disease over time. Thus, weight gain in both type I and type II diabetes may be associated with insulin resistance, worsening diabetes and increased doses of insulin or drug therapy required for successful glycaemic control.
Insulin detemir is not associated with undesirable weight gain
Insulin detemir is a novel acylated soluble insulin analogue designed to bind reversibly to albumin in interstitial fluid and in the circulation. This produces a long-acting insulin with less variability from injection to injection and a more consistent profile, compared with other basal insulins. 25 In 6-and 12-month studies of basal-bolus therapy in type I and type II diabetes, consistent and significant favourable weight changes compared with NPH have been demonstrated [26] [27] [28] [29] [30] [31] [32] [33] (Figure 4) .
Phase 3 clinical studies comparing insulin detemir with NPH insulin have been remarkably consistent in showing a significantly reduced risk of weight gain at equivalent levels of glycaemic control. For example, in one 6-month study of patients with type I diabetes (basal insulin given once-daily), the insulin detemir-treated cohort had a mean weight change of -0.2 vs 0.4 kg for NPH, baseline adjusted mean difference 0.5 kg, P ¼ 0.003. 28 HbA 1c values were similar at Insulin detemir and weight stability A Fritsche and H Häring the end of the study (insulin detemir, 8.30%; NPH, 8.41%; difference, P ¼ 0.083). In a 12-month study with twice-daily basal insulin and bolus human insulin (HI), the disparity was even greater. Weight change in the insulin detemir-treated group was À0.3 vs 1.4 kg for NPH, P ¼ 0.002. 30 Significantly less weight gain was also shown in type II diabetes. In a study of 6 months' therapy, the HbA 1c -adjusted weight change for insulin detemir was 1.0 vs 1.8 kg for NPH, P ¼ 0.02. 33 De Leeuw et al compared insulin detemir with NPH in a basal-bolus regimen for 12 months, with mealtime insulin aspart. 27 Over the study period, HbA 1c -adjusted weight remained stable for the group receiving insulin detemir (mean weight loss 0.1 kg), while the NPH group gained a mean of 1.2 kg. The difference in weight was maintained, and after 1 y the HbA 1c -adjusted weight difference was 1.44 kg (P ¼ 0.0002) ( Figure 5 ).
Why do people with diabetes gain weight on insulin?
In attempting to understand the underlying reasons for the results of the insulin detemir clinical studies, we must first consider why people with diabetes gain weight on insulin. Insulin lowers blood glucose by stimulating glucose uptake in peripheral tissues such as skeletal muscle, and by suppressing hepatic gluconeogenesis and glycogenolysis. Insulin also crosses the blood-brain barrier and, through action on CNS receptors, reduces appetite and therefore energy intake. 34 Insulin therapy endeavours to enable patients to replicate the normal physiological insulin response. However, in healthy individuals, insulin first passes through the liver where up to 50% is removed, and endogenous glucose production is suppressed, before entering the peripheral circulation. Treatment with subcutaneous exogenous insulin produces higher levels of peripheral insulin relative to hepatic levels compared with levels in healthy individuals. When good glycaemic control is achieved with exogenous insulin, blood glucose is utilised effectively and any excess energy intake is more likely to be retained and stored as fat. Thus, it is not unexpected that IIT regimens may produce weight gain when initiated in previously poorly controlled patients. This occurs through decreasing glycosuria, and also by insulin-stimulated lipogenesis. In a study of six patients with type I diabetes, 35 detailed measurements of energy expenditure and body composition were performed while patients were on conventional insulin therapy, and again after 2 months of IIT. After IIT, mean HbA 1c values decreased from 12.970.9 to 9.670.6% (Po0.01), body weight increased by 2.670.8 kg, with fat mass increasing by 2.470.8 kg, while lean body mass did not increase. Rates of energy expenditure decreased by approximately 5% (by 118732 kcal/day, Po0.05). The investigation found that correction of glycosuria with IIT contributed 70% to the positive energy balance leading to an increase in body fat, while reduction in metabolic rate contributed the rest. In type II diabetes, Bagg et al 36 demonstrated a significant mean weight increase in people on IIT as compared with conventional insulin therapy for 20 weeks (n ¼ 43, 3.270.8 kg vs 0.0270.7 kg, P ¼ 0.003). Fat-free mass increased by a mean of 1.8 kg in the IIT cohort, with the remainder of weight increase being fat mass (mean 1.65 kg). These and other studies have shown that weight gain may be mainly fat, or both lean and fat mass. Eating as a defence against hypoglycaemic episodes is a further cause of weight gain in some people with diabetes. 37 Immediate fears of hypoglycaemia, and especially nocturnal hypoglycaemia, can outweigh concerns about risks of serious complications due to suboptimal blood glucose control. It has, however, been posited that a positive correlation between risk of hypoglycaemic episodes and weight gain will not be observed. This is because patients who fear hypoglycaemia or experience its symptoms will be likely to eat more, thus avoiding hypoglycaemia, but gaining weight.
In patients transferring to more intensive diabetes treatment regimens, there may be multiple mechanisms for weight gain if energy intake is not reduced or closely managed. It is not surprising, therefore, that weight gain Haak et al. 33 Hermansen et al. 32 Home et al. 31 Standl et al. 30 Pieber et al. 29 Russell-Jones et al. 28 De Leeuw et al. 27 Vague et al. 26 Mean change in body weight (kg) Insulin detemir NPH insulin Months Change in weight (kg) Figure 5 Weight stability was maintained with insulin detemir for 12 months. 27 Insulin detemir and weight stability A Fritsche and H Häring S44 may be seen as an inevitable consequence of diabetes treatment, as the disease progresses over time, whatever therapy is employed to control blood glucose.
Why might insulin detemir be weight neutral?
There have been a number of hypotheses as to why there is a lack of undesirable weight gain with insulin detemir. Basal-bolus therapy with HI and basal NPH does not closely follow the natural insulin profile, due to the slow rise and fall of HI plasma levels when injected preprandially. Additionally, NPH has a duration of action of less than 24 h, with a tendency to produce peak levels leading to unexpected hypoglycaemia. Long-acting insulin analogues aim to reproduce the consistent, low overnight basal insulin levels of normal physiology better than NPH. Unlike HI, the short postprandial action of mealtime insulin analogues makes very little contribution to maintenance of basal insulin levels. The longer duration of action for mealtime HI contributes to basal insulin levels but provides suboptimal prandial glucose control. 38 A consequence of the time-action profile for rapid-acting analogues is that higher doses of basal insulin are needed than those required with HI. 39 Thus, a smooth and predictable pharmacokinetic profile is essential. Variations in duration of action or maximum insulin levels will leave patients vulnerable to hypoglycaemia, especially at night. Fear of hypoglycaemia results in behaviour intended to avoid the possibility of low blood glucose, including defensive eating, which is likely to result in weight gain. Many studies have shown insulin detemir to be associated with a significant reduction in within-subject variability of effect from injection to injection, 26, 33 and this has correlated with a reduced risk of hypoglycaemia. 40 There were also significantly fewer episodes of nocturnal hypoglycaemia for insulin detemir vs NPH. [26] [27] [28] Unlike other insulin analogues, insulin detemir is 98% bound to plasma albumin. As albumin passes freely into the liver from hepatic sinusoids, this could lead to a preferential hepatic insulin action for insulin detemir; an accompanying relative reduction in the peripheral effect could result in less weight gain.
Insulin passes through the blood-brain barrier and has effects on many areas of the brain, including inhibition of appetite. It has been speculated that insulin detemir could act more effectively on CNS receptors or it could cross the blood-brain barrier at a higher rate than other exogenous insulins. The effect of this hypothetical increase in brain action of insulin detemir could be to reduce appetite. With insulin detemir providing a more consistent basal profile, it is possible that weight gain will become less of a problem, as fear of hypoglycaemia recedes. However, further investigation is required to establish whether, and to what extent, these various hypotheses of insulin detemir mechanisms of action may affect weight.
Conclusion
Weight gain is not an inevitable consequence of diabetes therapy, but it is often a significant challenge for patients receiving insulin treatment, especially IIT, or combining insulin with OADs. Reluctance to initiate insulin or a subsequent negative experience of weight gain may lead to suboptimal therapy or nonadherence, with resulting poor glycaemic control. For patients with diabetes, the benefits of optimising glycaemic control are unambiguous in terms of decreased complications and mortality. IIT offers one of the best opportunities for effective diabetes self-management for many diverse patient groups, enabling them to achieve improved glycaemic control while maintaining flexibility in their lifestyles. Significant weight neutrality and consistent HbA 1c control have been demonstrated with insulin detemir in studies comparing it with NPH insulin in basal-bolus regimens. This may be a consequence of the increased predictability and smoother, more consistent pharmacodynamic profile of insulin detemir, resulting in reduced risks of hypoglycaemia. Patients may be able to reduce defensive eating against hypoglycaemia while maintaining more optimal blood glucose levels. The resulting weight stability is likely to have positive consequences for the immediate and long-term health of many diabetes patients.
